deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03590574

Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma

Sponsor: Autolus Limited

Conditions Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Peripheral T-Cell Lymphoma, Not Otherwise Specified T Cell Non-Hodgkin Lymphoma
Interventions AUTO4
Updated 14 times since 2018 Last updated: May 12, 2025 Started: Aug 30, 2018 Primary completion: Dec 12, 2024 Completion: Dec 12, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma and is currently completed. Autolus Limited leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Aug 2019 · 6 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Nov 2020 · 8 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Mar 2023 · 12 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  3. Oct 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 9 earlier versions

  1. Mar 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Mar 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Nov 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Autolus Limited
Data source: Autolus Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations